Skip to main content
. 2021 Jan 9;14:100293. doi: 10.1016/j.ynstr.2021.100293

Fig. 1.

Fig. 1

Effects of selective and dual inhibitors of FAAH and MAGL on stress-coping behavior in the TST. Effects of the selective FAAH inhibitor PF-3845 (1, 3 or 10 mg/kg, i.p.) on the latency to the first episode of immobility (A) and the total immobility time (B) in WT mice (n = 9–10 mice per group). Effects of the selective MAGL inhibitor JZL184 (2, 10 or 40 mg/kg, i.p.) on the latency to the first episode of immobility (C) and the total immobility time (D) in WT mice (n = 9–11 per group). Effects of the dual FAAH/MAGL inhibitor JZL195 (3, 8 or 20 mg/kg, i.p.) on the latency to the first episode of immobility (E) and the total immobility time (F) in WT mice (n = 9–10 per group). Effects of the selective MAGL inhibitor JZL184 on the latency to the first episode of immobility (G) and the total immobility time (H) in FAAH KO mice (n = 11 per group). Bars are mean ± SEM. Symbols in the bars denote significant differences in the post hoc test after one-way ANOVA: (**)p < 0.01 and (***)p < 0.001 denote significant differences vs. the vehicle group; (aa)p < 0.01 and (aaa)p < 0.001 denote significant differences vs. the low-dose group; (b)p < 0.05, (bb)p < 0.01 and (bbb)p < 0.001 denote significant differences vs. the intermediate-dose group.